On 20 August 2026, Fresenius SE & Co. KGaA announced that it had raised approximately €300 million through the sale of 7.8 million shares in its subsidiary Fresenius Medical Care. The transaction’s net proceeds are earmarked to reduce the Fresenius Group’s net debt and will also be retained for future investment opportunities. The company expects the share sale to generate a book gain in the low to mid double‑digit million‑euro range, which will be reflected in the Group’s third‑quarter 2026 financial results. This capital‑raising move is presented as a means to strengthen the balance sheet while supporting ongoing strategic initiatives.